The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target The firm cites its positive physician survey on ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

A physician survey for Neurocrine Biosciences Inc's NBIX +1.72% Get Free Report Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine Biosciences ...

Learn more about whether Neurocrine Biosciences, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...

During the last three months, 16 analysts shared their evaluations of Neurocrine Biosciences NBIX +1.72% Get Free Report , revealing diverse outlooks from bullish to bearish. The following table ...

Iverson, born with a life-threatening heart condition, gets the wish of a lifetime to visit Disney World, bringing joy, hope ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

Neurocrine Biosciences, Inc. announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, ...

Waikato mum Ocean Armstrong initially said no to a guide dog, but now she’s thriving with the help of her four-legged pal ...